Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James M Trzaskos

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 26, 2007
The map kinase ERK regulates renal activity of cyclin-dependent kinase 2 in experimental glomerulonephritisDirk Bokemeyer, Darius Panek, Masashi Kitahara, et al.
The Journal of Biological Chemistry|August 2, 2003
Aggrecan protects cartilage collagen from proteolytic cleavageMichael A Pratta, Wenqing Yao, Carl Decicco, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2008
Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituentsGregory R Ott, Naoyuki Asakawa, Zhonghui Lu, et al.
Journal of Medicinal Chemistry|May 28, 2004
Sultam hydroxamates as novel matrix metalloproteinase inhibitorsRobert J Cherney, Ruowei Mo, Dayton T Meyer, et al.
Bioorganic & Medicinal Chemistry Letters|February 1, 2008
Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)Gregory R Ott, Naoyuki Asakawa, Rui-Qin Liu, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonistsDouglas G Batt, Gregory C Houghton, John Roderick, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2003
Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identificationChu-Biao Xue, Xiaohua He, John Roderick, et al.
Bioorganic & Medicinal Chemistry Letters|November 23, 2007
Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitorsJames J-W Duan, Lihua Chen, Zhonghui Lu, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2003
Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)James J-W Duan, Zhonghui Lu, Chu-Biao Xue, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2003
Both 5-arylidene-2-thioxodihydropyrimidine-4,6(1H,5H)-diones and 3-thioxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-ones are light-dependent tumor necrosis factor-alpha antagonistsMatthew E Voss, Percy H Carter, Andrew J Tebben, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 26, 2007
The map kinase ERK regulates renal activity of cyclin-dependent kinase 2 in experimental glomerulonephritisDirk Bokemeyer, Darius Panek, Masashi Kitahara, et al.
The Journal of Biological Chemistry|August 2, 2003
Aggrecan protects cartilage collagen from proteolytic cleavageMichael A Pratta, Wenqing Yao, Carl Decicco, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2008
Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituentsGregory R Ott, Naoyuki Asakawa, Zhonghui Lu, et al.
Journal of Medicinal Chemistry|May 28, 2004
Sultam hydroxamates as novel matrix metalloproteinase inhibitorsRobert J Cherney, Ruowei Mo, Dayton T Meyer, et al.
Bioorganic & Medicinal Chemistry Letters|February 1, 2008
Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)Gregory R Ott, Naoyuki Asakawa, Rui-Qin Liu, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonistsDouglas G Batt, Gregory C Houghton, John Roderick, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2003
Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identificationChu-Biao Xue, Xiaohua He, John Roderick, et al.
Bioorganic & Medicinal Chemistry Letters|November 23, 2007
Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitorsJames J-W Duan, Lihua Chen, Zhonghui Lu, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2003
Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)James J-W Duan, Zhonghui Lu, Chu-Biao Xue, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2003
Both 5-arylidene-2-thioxodihydropyrimidine-4,6(1H,5H)-diones and 3-thioxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-ones are light-dependent tumor necrosis factor-alpha antagonistsMatthew E Voss, Percy H Carter, Andrew J Tebben, et al.
Pageof 3